RxDoctor Payments DataLook up a doctor →

Joshua Hare, DO

Addiction Medicine · Chattanooga, TNNPI 1811121924

Payments from drug & device makers

$4,901in general payments, 2019–2025

Across 238 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$746
  • Spinefrontier, Inc.$649
  • Boston Scientific$540
  • Abbott$357
  • Painteq LLC$142
  • plus $1K from 33 others

What the payments were for

  • Food & beverage$4,87299%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,901 in reported general payments places this provider in the 90th percentile of 76 addiction medicine providers in Tennessee.

See all addiction medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$926,024
Medicare patients
619
Services billed
10,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,289$39,476
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,344$36,407
Buprenorphine92$34,637
RelistorMethylnaltrexone Bromide11$27,516
MovantikNaloxegol Oxalate39$18,160
ButransBuprenorphine27$14,863
BelbucaBuprenorphine Hcl18$11,182
Xtampza ErOxycodone Myristate15$8,884
LinzessLinaclotide16$8,445
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl65$8,035
Gabapentin594$7,577
ZtlidoLidocaine11$6,609
Oxycodone Hcl333$6,503
Hydromorphone ErHydromorphone Hcl11$4,553
Pregabalin284$4,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$746$27,51611 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$92$20,06533 claims
Redhill Biopharma Inc.Movantik$16$18,16039 claims
AbbVieLinzess$14$8,44516 claims
Scilex Pharmaceuticals Inc.Ztlido$34$6,60911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 76 addiction medicine providers in Tennessee.

Other addiction medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →